Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $5.51M | $1.32M | $30.0K | $89.1M | $84.3M |
| Revenue growth | — | — | -76.1% | -97.7% | 297063.3% | -5.5% |
| Operating income | -$32.9M | -$19.5M | -$35.5M | -$67.5M | -$3.08M | -$179M |
| Operating margin | — | -353.3% | -2698.8% | -225066.7% | -3.5% | -212.9% |
| Net income | -$32.9M | -$20.2M | -$34.7M | -$54.4M | $8.00M | -$171M |
| Net margin | — | -367.7% | -2635.4% | -181216.7% | 9.0% | -203.3% |
| EPS (diluted) | -$11.33 | -$0.70 | -$0.87 | -$0.57 | $0.08 | -$1.74 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$31.2M | -$17.6M | -$40.1M | -$59.3M | $13.5M | -$171M |
| Capital expenditures | $917K | $55.0K | $199K | $175K | $563K | $339K |
| Free cash flow | -$32.1M | -$17.6M | -$40.3M | -$59.4M | $13.0M | -$171M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $387M | $60.1M | $211M | $71.0M | $50.8M | $41.3M |
| Total assets | $395M | $61.4M | $281M | $233M | $351M | $328M |
| Total liabilities | $11.9M | $16.7M | $8.55M | $2.43M | $94.4M | $213M |
| Long-term debt | — | — | — | — | $0.00 | $96.4M |
| Shareholders' equity | -$14.1M | -$31.3M | $273M | $231M | $257M | $114M |
| Retained earnings | -$96.7M | -$42.3M | -$76.9M | -$131M | -$123M | -$295M |
| Shares (wtd avg diluted) | 34.7M | 28.9M | 40.0M | 95.2M | 102M | 98.6M |
Every figure is extracted from ARS Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.